What is Lifesci Capital’s Estimate for iBio Q2 Earnings?

iBio, Inc. (NYSE:IBIO) – Investment analysts at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for shares of iBio in a report issued on Thursday, December 18th. Lifesci Capital analyst P. Dolezal expects that the company will earn ($0.12) per share for the quarter. The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Lifesci Capital also issued estimates for iBio’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.47) EPS.

A number of other equities research analysts also recently issued reports on IBIO. Leerink Partners began coverage on shares of iBio in a research report on Friday, October 17th. They issued an “outperform” rating and a $2.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating on shares of iBio in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $4.00.

iBio Stock Performance

IBIO stock opened at $1.88 on Monday. The firm has a 50 day simple moving average of $1.42 and a 200 day simple moving average of $1.01. iBio has a 52 week low of $0.56 and a 52 week high of $6.89. The stock has a market cap of $42.28 million, a P/E ratio of -1.35 and a beta of 1.13. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.76 and a current ratio of 1.76.

Institutional Investors Weigh In On iBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP bought a new stake in iBio during the third quarter worth approximately $37,000. Cubist Systematic Strategies LLC acquired a new stake in shares of iBio in the first quarter worth $224,000. Citadel Advisors LLC acquired a new stake in shares of iBio in the third quarter worth $109,000. Boothbay Fund Management LLC boosted its holdings in shares of iBio by 10.9% during the 3rd quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock worth $146,000 after buying an additional 17,414 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in iBio in the 3rd quarter valued at $399,000. 7.90% of the stock is currently owned by institutional investors and hedge funds.

iBio Company Profile

iBio, Inc (NYSE: IBIO) is a biotechnology company that develops and manufactures plant-based biologics, including vaccines and therapeutic proteins. Leveraging proprietary technology derived from Nicotiana benthamiana, a relative of tobacco, iBio applies a molecular farming approach to produce complex proteins more rapidly and with greater scalability than traditional cell-culture methods. The company’s core expertise lies in its ability to design, express and purify recombinant proteins for both research and commercial applications.

Central to iBio’s operations is the iBio CDM™ (cGMP-Direct Manufacture) platform, an integrated system that enables end-to-end development and production of biologics.